BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
Barclays upgrades Sun Pharma to overweight
Barclays upgrades Sun Pharma to overweight from equalweight earlier. Risk reward ratio is now favorable for investors. Multiple negatives are priced into the valuation. Base case suggests a 27 per cent upside potential. Bear-case scenario implies a 18 per cent downside potential.